Evidence map›Paper›PMID 41701449›Full record

ReviewEJNMMI radiopharmacy and chemistry2026

Solving the limited availability of Astatine-211 from a European perspective: from production to the end user.

Sture Lindegren, Holger Jensen, Hans Van de Maele, Renata Mikolajczak, Haingo Rabarijaona, Emma Aneheim

Abstract readReview
In one paragraph

Review in EJNMMI radiopharmacy and chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. European journal of nuclear medicine and molecular imaging · 2026
    Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Sture LindegrenDepartment of Medical Radiation Sciences, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, SE41345, Gothenburg, Sweden. sture.lindegren@radfys.gu.se.ORCID http://orcid.org/0000-0003-4288-0467
Holger JensenDepartment of Clinical Physiology and Nuclear Medicine, Cyclotron and Radiochemistry unit, Rigshospitalet, Denmark.
Hans Van de MaeleORI Consult/PHSE International, Brussels, Belgium.
Renata MikolajczakRadioisotope Centre POLATOM, National Centre for Nuclear Research, 05-400, Otwock, Poland.
Haingo RabarijaonaORI Consult/PHSE International, Brussels, Belgium.
Emma AneheimDepartment of Medical Radiation Sciences, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, SE41345, Gothenburg, Sweden.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAstatine-211, MAIN BODY: This work is the result of European Cooperation in Science and Technology, COST Action CA 19114, Network for Optimized Astatine labeled Radiopharmaceuticals, NOAR, Work Group 1 assignments, focusing on all aspects on

conclusionWith all efforts in production and making

Indexed as

Astatine-211AvailabilityEuropeProduction

Identifiers

PMID41701449
PMCPMC12929731

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.